drugset / Trial / NCT00079742

A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis

NCT00079742

Phase 2 Completed 68 enrolled Genentech, Inc.
Treatment

Summary

This is a Phase II, multicenter, randomized, controlled, open-label trial of the safety and efficacy of Nutropin AQ administered subcutaneously (SC) daily in prepubertal children with CF and growth restriction.

Timeline

Start
2003-09
Primary completion
Completion
2007-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic Subcutaneous

Indications